Adjuvant API Polychemotherapy Improves DFS but Not Overall Survival in Uterine Sarcoma Radiotherapy

Share this content:
(ChemotherapyAdvisor) – An adjuvant chemotherapy regimen of doxorubicin, ifosfamide, and cisplatin is associated with improved disease-free survival (DFS), but not overall survival (OS), among patients undergoing radiotherapy for uterine sarcomas -- but the regimen is highly toxic, according to data from a randomized phase 3 multicenter clinical trial, reported in the Annals of Oncology.

The “adjuvant chemotherapy statistically increases the 3-year DFS in patients with uterine sarcomas,” reported lead author Patricia Pautier, MD, of the Department of Medical Oncology's Gyencologic Unit at the Gustave-Roussy Institute in Villejuif Cedex, France, and coauthors.

The phase 3 multicenter SARCGYN study (NCT00162721) enrolled 81 patients younger than age 66 years at diagnosis with uterine sarcoma, randomized to receive either radiotherapy alone (RT; 45 Gy in 1.8-Gy fractions over 5 weeks; n=39 patients) or 4 cycles of adjuvant API polychemotherapy (doxorubicin+cisplatin+ ifosfamide) + G-CSF (Granulocyte colony-stimulating factor), every 3 weeks, followed by pelvic RT.

Adjuvant polychemotherapy (API)-arm patients received 4 cycles of doxorubicin (50mg/m2 on day 1), ifosfamide (3g/m2 on days 1 & 2), cisplatin (75 mg/m2 on day 3).

“After a median follow-up of 4.3 years, 41/81 patients recurred, 15 in arm A [API] and 26 in Arm B [RT only],” the authors reported. “The 3-year DFS rate was 55% in API-arm patients and 41% in RT-only-arm patients (P=0.048). However, OS was not statistically-significantly different between the two arms (81% API vs 69% RT-only; P=0.4, n.s.)," the authors noted.

API toxicity was frequent and serious. API was associated with two (5%) patient deaths from septic shock following the fourth cycle. The two toxic deaths among API-arm patients likely played a role in the disappointing OS findings, the authors noted.

Grade 3 to 4 toxicities were common among API-arm patients, including anemia (58% of patients), neutropenia (58%), febrile neutropenia (24%), thrombocytopenia (76%), and Grade 3 renal toxicity (1%).

Along with previous randomized trials, the study “shows that addition of 4 cycles of API chemotherapy prior to adjuvant pelvic RT increases slightly the DFS,” the authors concluded. A less-toxic chemotherapeutic regimen “could be less effective,” they cautioned.

SARCGYN enrolled patients with uterine sarcomas, including 19 patients with carcinosarcomas, in addition to patients with leiomyosarcomas and high-grade stromal sarcomas, the authors reported. The study did not meet its enrollment accrual goals.  
    
Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs